Credit Suisse upgraded shares of Exelon (NYSE:EXC) from a neutral rating to an outperform rating in a report released on Thursday, TheFlyOnTheWall.com reports. Exelon Corporation (NYSE:EXC) shares after opening at $32.60 moved to $32.87 on last trade day and at the end of the day closed at $32.55. Company price to sales ratio in past twelve months was calculated as 1.12 and price to cash ratio as 17.32. Exelon Corporation (NYSE:EXC) showed a positive weekly performance of 6.23%.
The shares of Visa Inc (NYSE:V) fluctuated after the United States Court of Appeals for the District of Columbia Circuit found the ruling of the Federal Reserve concerning debit card swipe fees reasonable. Visa Inc (NYSE:V) shares advanced 0.70% in last trading session and ended the day on $223.37. V return on equity ratio is recorded as 23.60% and its return on assets is 17.90%. Visa Inc (NYSE:V) yearly performance is 42.62%.
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Peter Mueller sold 7,500 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $78.29, for a total transaction of $587,175.00. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares moved down -5.07% in last trading session and was closed at $73.83 while trading in range of $72.82 – $77.75 – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) year to date (YTD) performance is -0.63%.
Gilead Sciences Inc. (NASDAQ:GILD) was questioned about the costly new drug named Sovaldi. The drug cost $84,000 and is currently facing a resistance from Medicaid programs and the health insurers. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is -3.97%. On last trading day company shares ended up $72.07. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -9.64%. Analysts mean target price for the company is $100.17.
Leave a Reply